Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
Blood (2019)
  • John E. Godwin, Providence Portland Medical Center
  • Carmen Ballesteros-Merino, Providence Cancer Center, Earl A. Chiles Research Institute, PORTLAND, OR
  • Nikhil Lonberg, Earle A Chiles Research Institute, Portland, OR
  • Shawn Jensen, Earle A Chiles Research Institute, Portland, OR
  • Tarsem Moudgil, Earle A Chiles Research Institute, Portland, OR
  • Carlo B Bifulco, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR
  • Jon Wigginton, MacroGenics, Inc., Rockville, MD
  • John Muth, MacroGenics, Inc., Rockville, MD
  • Jan K Davidson-Moncada, MacroGenics, Inc., Washington, DC
  • Bernard Fox, Providence Cancer Center, Earle A. Chiles Research Institute, Portland, OR
Link
Disciplines
Publication Date
November 13, 2019
DOI
10.1182/BLOOD-2019-128485
Citation Information
John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn Jensen, et al.. "Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients" Blood Vol. 134 (2019) p. 1410 - 1410
Available at: http://works.bepress.com/carlo-bifulco/60/